利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

51 条记录 (耗时 0.054 秒)

    Optical waveguide device
    2.
    发明授权
    Optical waveguide device 失效
    光波导器件

    公开(公告)号：US06980705B2

    公开(公告)日：2005-12-27

    申请号：US10451435

    申请日：2001-11-28

    申请人： Yasuyuki Miyama ,  Hirotoshi Nagata ,  Toshihiro Sakamoto

    发明人： Yasuyuki Miyama ,  Hirotoshi Nagata ,  Toshihiro Sakamoto

    IPC分类号： G02B6/12 ,  G02F1/03 ,  G02F1/035

    CPC分类号： G02F1/0322 ,  G02F1/035 ,  G02F1/0356 ,  G02F2201/07 ,  G02F2201/16 ,  G02F2203/21 ,  G02F2203/50

    摘要： A first film (8) is formed between a substrate (1) and a signal electrode (3); ground electrodes (5) and (6) which constitute an optical waveguide device (10), and a second film (9) is formed between the substrate (1) and a signal electrode (4); ground electrodes (6) and (7). An optical phase modulator (10A) is composed of the substrate (1), an optical waveguide (2), the signal electrode (3), the ground electrodes (5) and (6), and the first film (8). An optical intensity modulator (10B) is composed of the substrate (1), the optical waveguide (2), the signal electrode (4), the ground electrodes (6) and (7), and the second film (9). The optical waveguide device (10) is composed of the optical phase modulator (10A) and the optical intensity modulator (10B), which are integrated monolithically.

    摘要翻译： 第一膜（8）形成在基板（1）和信号电极（3）之间; 构成光波导装置（10）的接地电极（5）和（6），在基板（1）和信号电极（4）之间形成第二膜（9）。 接地电极（6）和（7）。 光学相位调制器（10A）由基片（1），光波导（2），信号电极（3），接地电极（5）和（6）和第一薄膜（8）构成。 光强度调制器（10 B）由基板（1），光波导（2），信号电极（4），接地电极（6）和（7）和第二膜（9）构成。 光波导装置（10）由光学相位调制器（10A）和光强度调制器（10B）组成，其被整体地集成。

    Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
    5.
    发明授权
    Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient 失效
    黑色素浓缩激素受体拮抗剂含有哌啶衍生物作为活性成分

    公开(公告)号：US07727998B2

    公开(公告)日：2010-06-01

    申请号：US10544261

    申请日：2004-02-09

    申请人： Minoru Moriya ,  Toshihiro Sakamoto ,  Makoto Ishikawa ,  Akio Kanatani ,  Takehiro Fukami

    发明人： Minoru Moriya ,  Toshihiro Sakamoto ,  Makoto Ishikawa ,  Akio Kanatani ,  Takehiro Fukami

    IPC分类号： A61K31/4545 ,  C07D491/10

    CPC分类号： C07D401/04 ,  A61K31/438 ,  A61K31/4439 ,  A61K31/445 ,  C07D211/26 ,  C07D491/10

    摘要： The invention provides melanin-concentrating hormone receptor antagonists containing as the active ingredient piperidine derivatives represented by the general formula [I]: [wherein R1 is hydrogen, hydroxyl, lower alkyl, or the like; R2, R3a, R3b, R4a, R4b, R5a, R5b and R6 each stands for hydrogen, halogen, or the like; W1 and W2 each independently stands for —O—, —CH2—, or the like; Y1, Y2, Y3 and Y4 stand for —CH—, —CF—, —N—, or the like; Z stands for lower alkyl, an aliphatic heterocyclic group, or the like; Ar is a mono- or bi-cyclic aliphatic heterocycle or an aromatic heterocycle; and n is an integer of 1 to 8]. The compounds act as antagonist against melanin-concentrating hormone receptor and are useful as drugs for central diseases, circulatory diseases, or metabolic diseases.

    摘要翻译： 本发明提供了含有作为活性成分的通式[I]表示的哌啶衍生物的黑色素浓缩激素受体拮抗剂：其中R1是氢，羟基，低级烷基等; R2，R3a，R3b，R4a，R4b，R5a，R5b和R6各自代表氢，卤素等; W1和W2各自独立地代表-O-，-CH2-等; Y1，Y2，Y3和Y4代表-CH-，-CF-，-N-等; Z代表低级烷基，脂族杂环基等; Ar是单环或双环脂族杂环或芳族杂环; n为1〜8的整数]。 该化合物作为拮抗黑素浓缩激素受体的拮抗剂，可用作中枢疾病，循环系统疾病或代谢疾病的药物。

    Phenylpyridone Derivative
    7.
    发明申请
    Phenylpyridone Derivative 失效
    苯基吡啶酮衍生物

    公开(公告)号：US20090137587A1

    公开(公告)日：2009-05-28

    申请号：US11990889

    申请日：2006-08-23

    申请人： Akira Naya ,  Toshihiro Sakamoto ,  Yuji Haga ,  Norikazu Otake

    发明人： Akira Naya ,  Toshihiro Sakamoto ,  Yuji Haga ,  Norikazu Otake

    IPC分类号： A61K31/444 ,  C07D213/64 ,  C07D401/02 ,  C07D413/02 ,  A61K31/4439 ,  A61P9/00 ,  A61P25/00 ,  A61P3/00 ,  C07D401/14 ,  A61K31/5377 ,  A61K31/4545

    CPC分类号： C07D213/69 ,  C07D213/64 ,  C07D401/10 ,  C07D413/10

    摘要： A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH═CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.

    摘要翻译： 作为活性成分，含有式（I）所示的化合物：其中，R 1和R 2分别独立地表示氢原子，低级烷基等，或者与连接有L，Z 2和R 1的氮原子一起形成 可以形成脂族氮杂环基，并且R 1和R 2与它们所连接的氮原子一起形成脂族氮杂环基; X表示次甲基或氮原子; Y表示-CH 2 -O - ， - CH-CH-等; Z1表示单键，C1-4亚烷基等; Z2表示单键或C1-4亚烷基; L表示亚甲基，C3-8亚环烷基等; Ar表示芳族碳环基等。 该化合物可用作中枢神经系统疾病，心血管疾病或代谢疾病的药物。

    Imidazopyridine Derivatives
    8.
    发明申请
    Imidazopyridine Derivatives 失效
    咪唑并吡啶衍生物

    公开(公告)号：US20080200494A1

    公开(公告)日：2008-08-21

    申请号：US10567269

    申请日：2004-08-13

    申请人： Hiroyuki Kishino ,  Minoru Moriya ,  Toshihiro Sakamoto ,  Hidekazu Takahashi ,  Shunji Sakuraba ,  Takao Suzuki ,  Akio Kanatani

    发明人： Hiroyuki Kishino ,  Minoru Moriya ,  Toshihiro Sakamoto ,  Hidekazu Takahashi ,  Shunji Sakuraba ,  Takao Suzuki ,  Akio Kanatani

    IPC分类号： A61K31/437 ,  A61P3/10 ,  C07D471/04

    CPC分类号： C07D471/04

    摘要： The invention provides imidazopyridine derivatives represented by the general formula [I] [in which R1 and R2 may be the same or different and stand for C1-6 alkyl or the like, R3 and R4 stand for hydrogen atom, methyl group or the like, W stands for mono- or bi-cyclic 3- to 8-membered aromatic or aliphatic heterocycle or the like, and Ar stands for optionally substituted aromatic heterocycle or the like]. These compounds act as melanin-concentrating hormone receptor antagonist and are useful as medicines for central nervous system disorders, cardiovascular system disorders and metabolic disorders.

    摘要翻译： 本发明提供由通式[I]表示的咪唑并吡啶衍生物[其中R 1'和R 2'可以相同或不同，代表C 1〜 6个烷基等，R 3和R 4代表氢原子，甲基等，W代表单环或双环3 - 至8-元芳族或脂族杂环等，Ar表示任选取代的芳族杂环等〕。 这些化合物作为黑色素浓缩激素受体拮抗剂起作用，可用作中枢神经系统疾病，心血管系统疾病和代谢紊乱的药物。

    Spiro compounds
    10.
    发明授权
    Spiro compounds 失效
    螺环化合物

    公开(公告)号：US06462053B1

    公开(公告)日：2002-10-08

    申请号：US10101221

    申请日：2002-03-20

    申请人： Takehiro Fukami ,  Akio Kanatani ,  Akane Ishihara ,  Yasuyuki Ishii ,  Toshiyuki Takahashi ,  Yuji Haga ,  Toshihiro Sakamoto ,  Takahiro Itoh

    发明人： Takehiro Fukami ,  Akio Kanatani ,  Akane Ishihara ,  Yasuyuki Ishii ,  Toshiyuki Takahashi ,  Yuji Haga ,  Toshihiro Sakamoto ,  Takahiro Itoh

    IPC分类号： A61K34355

    CPC分类号： C07D405/12 ,  C07D213/61 ,  C07D307/94 ,  C07D471/10 ,  C07D491/10

    摘要： A method for treating a cardiovascular disorder, which involves administering to a patient in need a therapeutically effective amount of a compound of formula (I): wherein Ar1 represents an aryl or heteroaryl which may be substituted, the substituent being selected from the group consisting of halogen, nitro, lower alkyl, halo(lower) alkyl, hydroxy(lower) alkyl, cyclo(lower) alkyl, lower alkenyl, lower alkoxy, halo(lower) alkoxy, lower alkylthio, carboxyl, lower alkanoyl, lower alkoxycarbonyl, lower alkylene optionally substituted with oxo, and a group represented by the formula —Q—Ar2; Ar2 represents an aryl or heteroaryl which may be substituted, the substituent being selected from the group consisting of halogen, cyano, lower alkyl, halo(lower) alkyl, hydroxy(lower) alkyl, hydroxy, lower alkoxy, halo(lower) alkoxy, lower alkylamino, di-lower alkylamino, lower alkanoyl and aryl: n represents 0 or 1; Q represents a single bond or carbonyl; T, U, V and W each independently represent a nitrogen atom or a methine group which may have a substituent selected from the group consisting of halogen, lower alkyl, hydroxy and lower alkoxy, wherein at least two of which represent said methine group; X represents methine; Y represents an imino which may be substituted with lower alkyl, or oxygen; or a salt or ester thereof.

    摘要翻译： 一种治疗心血管疾病的方法，其涉及向需要的患者施用治疗有效量的式（I）化合物：其中Ar1表示可被取代的芳基或杂芳基，所述取代基选自 卤素，硝基，低级烷基，卤代（低级）烷基，羟基（低级）烷基，环（低级）烷基，低级烯基，低级烷氧基，卤代（低级）烷氧基，低级烷硫基，羧基，低级烷酰基，低级烷氧基羰基， 任选被氧代取代的基团和由式-Q-Ar 2表示的基团; Ar 2表示可被取代的芳基或杂芳基，所述取代基选自卤素，氰基，低级烷基，卤代（低级）烷基， 羟基（低级）烷基，羟基，低级烷氧基，卤代（低级）烷氧基，低级烷基氨基，二低级烷基氨基，低级烷酰基和芳基：n表示0或1; Q表示单键或羰基; T，U， W各自独立地表示硝基 可以具有选自卤素，低级烷基，羟基和低级烷氧基的取代基的次甲基，其中至少两个表示所述次甲基; X表示次甲基; Y表示可以被取代的亚氨基 与低级烷基或氧; 或其盐或酯。